Clinical Trials Logo

Clinical Trial Summary

This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To use a genome-wide association analysis to identify novel genetic variants that confer susceptibility to Wilms tumor.

II. To improve our understanding of the genetic architecture and etiology of Wilms tumor.

III. To facilitate the identification of genetic markers that are associated with an increased risk of developing of Wilms tumor and/or those at risk of aggressive disease, relapse, additional tumors and/or cancer in their offspring.

OUTLINE:

Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA). ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT01808079
Study type Observational
Source Children's Oncology Group
Contact
Status Completed
Phase N/A
Start date October 2009
Completion date November 2009

See also
  Status Clinical Trial Phase
Recruiting NCT04322318 - A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Phase 2
Active, not recruiting NCT00352534 - Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Phase 3
Not yet recruiting NCT06401330 - A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) Phase 3
Active, not recruiting NCT00945009 - Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Phase 3
Active, not recruiting NCT00379340 - Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Phase 3